1. Home
  2. FTEL vs GRI Comparison

FTEL vs GRI Comparison

Compare FTEL & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fitell Corporation

FTEL

Fitell Corporation

HOLD

Current Price

$0.43

Market Cap

1.7M

Sector

N/A

ML Signal

HOLD

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$0.29

Market Cap

1.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTEL
GRI
Founded
2007
2018
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7M
1.9M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
FTEL
GRI
Price
$0.43
$0.29
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$23.00
AVG Volume (30 Days)
2.4M
4.6M
Earning Date
11-17-2025
11-14-2025
Dividend Yield
49.02%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,200,138.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.42
N/A
52 Week Low
$0.40
$0.22
52 Week High
$187.68
$15.47

Technical Indicators

Market Signals
Indicator
FTEL
GRI
Relative Strength Index (RSI) 32.85 24.69
Support Level $0.47 $0.23
Resistance Level $0.58 $0.31
Average True Range (ATR) 0.08 0.05
MACD 0.02 0.04
Stochastic Oscillator 12.31 32.14

Price Performance

Historical Comparison
FTEL
GRI

About FTEL Fitell Corporation

Fitell Corp conducts its primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiary, serving personal training studios and commercial gyms. Its product coverage includes four proprietary brands: Muscle Motion for strength-training equipment, Rapid Motion with a focus on commercial items, FleetX for cardio equipment, and Harison for cardio, strength, recovery, and conditioning products. The Company operates in one segment, trading gym equipment, and also provides licensing services and gym equipment to overseas gym studios. Majority of its business is conducted in Australia via its e-commerce platform and third-party sites, with maximum revenue earned from retail.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: